Analysts await Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $1.13 EPS, down 20.35% or $0.23 from last year’s $1.36 per share.

At the moment 26 analysts are watching Teva Pharmaceutical Industries Limited (NASDAQ:TEVA), 11 rate it “Buy”, 10 “Outperform”, 5 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 17 analysts have a mean sales target of 4,896.47 million. For the quarter ending Sep-16, 16 analysts have a mean sales target of 6,467.49 million whilst for the year ending Dec-16, 16 analysts have a mean target of 22,348.70 million.

In terms of earnings per share, 18 analysts have a 1.18 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 18 analysts have a 1.42 EPS mean target and for the quarter ending Sep-16 there are 18 estimates of 5.26 EPS.

The biggest institutional shareholders in Teva Pharmaceutical Industries Limited include Fidelity Management & Research Company which owns 60 million shares in the company valued at $3.33 B million. Viking Global Investors LP is the second biggest holder with 25 million shares currently valued at 1.64 B million whilst Paulson & Company Inc has 20 million shares valued at 1.34 B million.

Total shares held by institutions as of the most recent company filings are 591,904,950 with a reported 80,855,547 bought and 40,459,324 sold. These holdings make up 65.56% of the company’s outstanding shares.

The stock decreased 6.68% or $3.6 during the last trading session, hitting $50.79. Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) has fallen 16.3% over the past 6 months and is downtrending.